Plasma biomarker signatures in patients with rapidly progressive dementia
Аннотация
Abstract INTRODUCTION Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions. METHODS Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging. RESULTS Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p‐tau)217 and p‐tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment–non‐responsive causes of RPD. DISCUSSION Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts.